Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05291468
Other study ID # NL73729.100.21
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 1, 2023
Est. completion date June 30, 2023

Study information

Verified date December 2022
Source St. Antonius Hospital
Contact Marcel Veltkamp, Dr.
Phone +31883201425
Email m.veltkamp@antoniusziekenhuis.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study it is investigated whether treatment with azithromycin in combination with doxycycline reduces the bacterial load of C. acnes in granulomatous tissue of patients with sarcoidosis and subsequently decreases the inflammatory activation measured by FDG uptake and serum biomarkers.


Description:

Sarcoidosis is a multisystemic disease with unknown origin mostly affecting intrathoracic lymph nodes, lungs and skin. Sarcoidosis is characterized by the formation of non-caseating granulomas causing a variety of symptoms based on the organs involved. Although frequently described as a benign disease, mortality rate has been estimated to be around 11.0 per 1000 person-years in patients with sarcoidosis, with respiratory failure as the most common cause of death in the western world. The main treatment indication in sarcoidosis is risk of organ failure. In the literature the need for systemic treatment varies between 20-70%. Since there is no curative treatment for sarcoidosis, treatment is focused on suppression of the inflammation. This is usually done with the use of immunosuppressive drugs, such as prednisone and/or methotrexate, and in patients with severe refractory disease infliximab. It is well known that treatment with immunosuppressive drugs is associated with burdensome side effects for patients and impaired quality of life. Considerable research has been done on the possible role C. acnes in the pathogenesis of sarcoidosis. In a recent work of our own group it was shown that presence of C. acnes within granulomatous tissue can be detected in 41% of Dutch patients with sarcoidosis. Azithromycin has an inhibiting effect on several bacterial infections, such as C. acnes. Therefore, sarcoidosis patients with C. acnes in the granulomatous tissue might benefit from treatment with azithromycin. Given the fact that microbial resistance to azithromycin is relatively easy to develop, it is common practice to treat C. acnes with a combination of azithromycin and doxycycline.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date June 30, 2023
Est. primary completion date April 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Biopsy proven sarcoidosis. - No treatment indication for the sarcoidosis - Inflammatory activity according to FDG-PET scan at baseline - SUVmax above 3 in the lung and/or above 5 in mediastinum/hili Exclusion Criteria: - Increased duration of QT interval (>440ms for men and >450ms for women) on ECG - Hearing deficits, as this is a possible side effect of azithromycin - Being pregnant or breastfeeding at time of inclusion

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
FDG-PET/CT
Patients will be randomized in a 1:1 ratio to either receive a combination of doxycycline and azithromycin or placebo during 3 months, after which the inflammatory state of disease is measured by FDG-PET/CT and serum biomarkers. If patients have cutaneous sarcoidosis, a skin biopsy will be performed at baseline and at the end of the study.

Locations

Country Name City State
Netherlands St. Antonius Hospital Nieuwegein Utrecht

Sponsors (2)

Lead Sponsor Collaborator
St. Antonius Hospital ZonMw: The Netherlands Organisation for Health Research and Development

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other serum biomarker: ACE Determine whether treatment with azithromycin and doxycycline changes levels of serum biomarker Angiotensin Converting Enzyme (ACE) in U/I in sarcoidosis patients 2 weeks
Other serum biomarker: IL-2R Determine whether treatment with azithromycin and doxycycline changes levels of serum biomarker interleukin-2receptro (IL-2R) in pg/mL in sarcoidosis patients 2 weeks
Primary SUVmax Difference of standarized uptake value (SUVmax) uptake after treatment with antibiotics between patients with and without C. acnes in their granuloma 2 weeks
Secondary lung function Difference in FVC after treatment with antibiotics between patients with and without C. acnes in their granulomatous tissue 2 weeks
Secondary quality of life according to questionnaire Monitor quality of life for patients treated with antibiotics compared to patients receiving placebo, measured by King's Sarcoidosis Questionnaire that is taken at baseline and end of study. QOL is measured with the King's Sarcoidosis Questionnaire (KSQ), which is a validated questionnare on sarcoidosis with 5 scales and 29 items. 2 weeks
See also
  Status Clinical Trial Phase
Completed NCT04020380 - Azithromycin a Treatment for Pulmonary Sarcoidosis Phase 2
Recruiting NCT03260556 - Pirfenidone for Progressive Fibrotic Sarcoidosis Phase 4
Completed NCT05759221 - Peripheral Airway Biopsy in Sarcoidosis N/A
Completed NCT03336736 - The Role of Physical Activity and Diet Within Pulmonary Sarcoidosis
Completed NCT03140644 - SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis N/A
Completed NCT03793439 - Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis Phase 1
Recruiting NCT04895111 - Endobronchial Ultrasound Strain Elastography in Sarcoidosis
Not yet recruiting NCT05910554 - Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis Phase 2
Recruiting NCT05374447 - Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy N/A
Active, not recruiting NCT04314193 - Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis Phase 4
Completed NCT03727451 - A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis Phase 2
Recruiting NCT05746039 - Feasibility of Semaglutide in Advanced Lung Disease Phase 1/Phase 2
Completed NCT04803617 - Investigation of Pectoralis Muscle Strength in Elderly With Interstitial Lung Disease
Recruiting NCT03145922 - Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis
Completed NCT00279708 - Atorvastatin to Treat Pulmonary Sarcoidosis Phase 2
Recruiting NCT05567133 - Risk Indicators of Sarcoidosis Evolution-Unified Protocol
Completed NCT05311150 - An RCT of NBI vs. White Light Guided Endobronchial Biopsy in Suspected Sarcoidosis N/A
Completed NCT05811962 - The Diagnostic and Prognostic Role of SAA in Intrathoracic Sarcoidosis
Completed NCT03320070 - Acthar Gel in Participants With Pulmonary Sarcoidosis Phase 4
Completed NCT03324503 - A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis N/A